Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children.
J Cyst Fibros
; 16(5): 631-636, 2017 Sep.
Article
en En
| MEDLINE
| ID: mdl-28416415
ABSTRACT
BACKGROUND:
Fecal calprotectin may be used as a non-invasive method to assess the effect of novel therapies on the gut in cystic fibrosis (CF).METHOD:
Stools from CF patients and healthy controls (HC) (0-10years old) were prospectively collected for evaluation of temporal trends.RESULTS:
130 CF samples (64 subjects) and 114 HC samples (101 subjects) were collected. Overall, fecal calprotectin levels were different in CF patients and HC from 0 to 10years (P=0.0002). Fecal calprotectin in CF was significantly lower than HC from 0 to 1years (P=0.03) and demonstrated an upward trajectory until 4years. From >4 to 10years calprotectin was consistently higher in CF patients compared with HC (P=0.007).CONCLUSIONS:
Fecal calprotectin levels in children with CF and HC were age-dependent and had distinct trajectories. Careful interpretation of calprotectin is required if used in drug trials for CF, particularly in children less than 4years old.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fibrosis Quística
/
Complejo de Antígeno L1 de Leucocito
/
Heces
/
Inflamación
/
Mucosa Intestinal
/
Intestinos
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
Límite:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
/
Newborn
Idioma:
En
Revista:
J Cyst Fibros
Año:
2017
Tipo del documento:
Article
País de afiliación:
Australia